Cargando…

Serious adverse events in African–American cancer patients with sickle cell trait and inherited haemoglobinopathies in a SEER-Medicare claims cohort

African–American (AA) cancer patients have long-experienced worse outcomes compared to non-Hispanic whites (NHW). No studies to date have evaluated the prognostic impact of sickle cell trait (SCT) and other inherited haemoglobinopathies, of which several are disproportionately high in the AA populat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hoag, Jessica R., Andemariam, Biree, Wang, Xiaoyan, Gregorio, David I., Jones, Beth A., Sporn, Jonathan, Salner, Andrew L., Swede, Helen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Brief Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6474269/ https://www.ncbi.nlm.nih.gov/pubmed/30890774 http://dx.doi.org/10.1038/s41416-019-0416-7

Ejemplares similares

Comparison of SEER Treatment Data With Medicare Claims
por: Noone, Anne-Michelle, et al.
Publicado: (2016)

Valsartan impedes epinephrine-induced ICAM-4 activation on normal, sickle cell trait and sickle cell disease red blood cells
por: Zhang, Jing, et al.
Publicado: (2019)

Patient Controlled Analgesia for Adults with Sickle Cell Disease Awaiting Admission from the Emergency Department
por: Santos, Josue, et al.
Publicado: (2016)

Measurement of skeletal related events in SEER-Medicare: a comparison of claims-based methods
por: Aly, Abdalla, et al.
Publicado: (2015)

Editorial for Special Issue “Newborn Screening for Sickle Cell Disease and other Haemoglobinopathies”
por: Colombatti, Raffaella, et al.
Publicado: (2019)

Using Pointwise Mutual Information for Breast Cancer Health Disparities Research With SEER-Medicare Claims
por: Egleston, Brian L., et al.
Publicado: (2023)

Annual Academy of Sickle Cell and Thalassaemia (ASCAT) conference: a summary of the proceedings
por: Strunk, Crawford, et al.
Publicado: (2020)

Haemoglobinopathies in Southeast Asia
por: Fucharoen, Suthat, et al.
Publicado: (2011)

Economic and Clinical Burden of Managing Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in the United States
por: Udeze, Chuka, et al.
Publicado: (2023)

Radioimmunotherapy with tositumomab and iodine-131 tositumomab for non-Hodgkin’s lymphoma
por: Andemariam, Biree, et al.
Publicado: (2007)

Improving Screening Programmes for Sickle Cell Disorders and Other Haemoglobinopathies in Europe: The Role of Patient Organisations
por: James, John, et al.
Publicado: (2019)

Correction to: Economic and Clinical Burden of Managing Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in the United States
por: Udeze, Chuka, et al.
Publicado: (2023)

GUIDELINES FOR THE DIAGNOSIS OF THE HAEMOGLOBINOPATHIES IN NIGERIA
por: Kotila, Taiwo R.
Publicado: (2010)

Haemoglobinopathies in tribal populations of India
por: Ghosh, Kanjaksha, et al.
Publicado: (2015)

Prenatal Diagnosis and Screening of the Haemoglobinopathies
por: Cao, Antonio, et al.
Publicado: (1999)

Multidisciplinary Care of Haemoglobinopathies in Qatar
Publicado: (2018)

Transgenic sickle cell disease mice have high mortality and dysregulated immune responses after vaccination
por: Szczepanek, Steven M., et al.
Publicado: (2013)

First and Second Level Haemoglobinopathies Diagnosis: Best Practices of the Italian Society of Thalassemia and Haemoglobinopathies (SITE)
por: Mandrile, Giorgia, et al.
Publicado: (2022)

Good Clinical Practice of the Italian Society of Thalassemia and Haemoglobinopathies (SITE) for the Management of Endocrine Complications in Patients with Haemoglobinopathies
por: Casale, Maddalena, et al.
Publicado: (2022)

Corpuscular Haemolytic Anaemias - Lepore Haemoglobinopathy
por: TUDORASCU, IULIA, et al.
Publicado: (2014)

Haemoglobinopathies from the cardiac point of view
por: Romano, Minna Moreira Dias
Publicado: (2019)

P113: INCIDENCE OF HAEMOGLOBINOPATHY IN SLOVAKIA
por: Fabryova, V, et al.
Publicado: (2022)

P117: THE INTERNATIONAL HAEMOGLOBINOPATHY RESEARCH NETWORK (INHERENT): AN INTERNATIONAL INITIATIVE TO STUDY THE ROLE OF GENETIC MODIFIERS IN HAEMOGLOBINOPATHIES
por: Kountouris, P, et al.
Publicado: (2022)

P1432: PATTERNS OF VOXELOTOR USE IN A MULTICENTER, REAL-WORLD STUDY OF PATIENTS WITH SICKLE CELL DISEASE
por: Andemariam, Biree, et al.
Publicado: (2023)

Burden of disease, treatment utilization, and the impact on education and employment in patients with sickle cell disease: A comparative analysis of high‐ and low‐ to middle‐income countries for the international Sickle Cell World Assessment Survey
por: Osunkwo, Ifeyinwa, et al.
Publicado: (2022)

P1444: AVASCULAR NECROSIS IN PATIENTS WITH SICKLE CELL DISEASE: A RETROSPECTIVE ANALYSIS AT A SPECIALIST HAEMOGLOBINOPATHY CENTRE
por: Loughran, Niamh, et al.
Publicado: (2023)

Haemoglobinopathies in Europe: health & migration policy perspectives
por: Aguilar Martinez, Patricia, et al.
Publicado: (2014)

Genetic Modifiers at the Crossroads of Personalised Medicine for Haemoglobinopathies
por: Stephanou, Coralea, et al.
Publicado: (2019)

Using DNA testing for the precise, definite, and low-cost diagnosis of sickle cell disease and other Haemoglobinopathies: findings from Tanzania
por: Christopher, Heavenlight, et al.
Publicado: (2021)

P1439: EPELEUTON, A NOVEL SYNTHETIC Ω-3 FATTY ACID, REDUCES ENDOTHELIAL ADHESION OF RED BLOOD CELLS FROM SICKLE CELL DISEASE PATIENTS UNDER PHYSIOLOGICAL FLOW CONDITIONS
por: Hamza, Moayed, et al.
Publicado: (2023)

Overview of the SEER—Medicare Health Outcomes Survey Linked Dataset
por: Ambs, Anita, et al.
Publicado: (2008)

Ethical issues in genetic counselling with special reference to haemoglobinopathies
por: Muthuswamy, Vasantha
Publicado: (2011)

Cohort profile: targeted antenatal screening for haemoglobinopathies in Basel
por: Amstad Bencaiova, Gabriela, et al.
Publicado: (2020)

Implementation of universal newborn bloodspot screening for sickle cell disease and other clinically significant haemoglobinopathies in England: screening results for 2005–7
por: Streetly, A, et al.
Publicado: (2009)

Poor Long-Term Efficacy of Prevnar-13 in Sickle Cell Disease Mice Is Associated with an Inability to Sustain Pneumococcal-Specific Antibody Titers
por: Szczepanek, Steven M., et al.
Publicado: (2016)

Hepatocellular Carcinoma Survival by Etiology: A SEER‐Medicare Database Analysis
por: Brar, Gagandeep, et al.
Publicado: (2020)

Opportunities for Personalizing Colorectal Cancer Care: An Analysis of SEER-Medicare Data
por: Rivers, Zachary T., et al.
Publicado: (2022)

Diagnostic rate estimation from Medicare records: Dependence on claim numbers and latent clinical features
por: Hogans, Beth, et al.
Publicado: (2023)

Haemoglobinopathies in Greece: prevention programme over the past 35 years
por: Loukopoulos, Dimitris
Publicado: (2011)

The role of religious leaders and faith organisations in haemoglobinopathies: a review
por: Toni-Uebari, Thelma K, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_hmmcq08rudh5viikivbf3tnfka